Pharming Group's (PHAR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Pharming Group (NASDAQ:PHAR - Free Report) in a research report released on Wednesday,Benzinga reports. HC Wainwright currently has a $37.00 price target on the stock.

A number of other analysts have also recently weighed in on PHAR. Jefferies Financial Group initiated coverage on Pharming Group in a research report on Monday. They issued a "buy" rating and a $14.00 price target on the stock. Oppenheimer decreased their price objective on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th.

Pharming Group Price Performance

PHAR traded up $0.53 during midday trading on Wednesday, reaching $9.27. 32,226 shares of the company's stock were exchanged, compared to its average volume of 5,238. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The business has a 50-day simple moving average of $8.21 and a two-hundred day simple moving average of $8.13. The firm has a market capitalization of $628.83 million, a price-to-earnings ratio of -36.38 and a beta of 0.05. Pharming Group has a one year low of $6.65 and a one year high of $13.20.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,110 shares of the company's stock after acquiring an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.